The Fidelity MSCI Health Care Index ETF (FHLC) and the State Street Health Care Select Sector SPDR ETF (XLV) both feature a low expense ratio of 0.08%, but they cater to different investment strategies. While XLV offers a concentrated portfolio with 60 large-cap holdings, FHLC boasts a broader approach with 365 positions, including mid- and small-cap stocks. This distinction is crucial for investors assessing their risk tolerance and income needs.
XLV provides a higher trailing-12-month dividend yield of 1.7% compared to FHLC’s 1.4%, appealing to income-focused investors. However, FHLC’s extensive diversification may attract those seeking growth potential, as smaller companies often experience faster expansion. Notably, XLV’s performance is heavily influenced by its top holdings, including Eli Lilly and Johnson & Johnson, which together account for over 25% of the fund.
Investors must weigh the trade-offs between concentrated blue-chip exposure and diversified growth potential when choosing between these two ETFs. Understanding these dynamics can significantly impact portfolio strategy in the healthcare sector.
Source: nasdaq.com